Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Harvard Bioscience (HBIO) Accumulated Depreciation & Amortization (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with $15.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 9.98% to $15.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $15.8 million, a 9.98% increase, with the full-year FY2024 number at $15.8 million, up 9.98% from a year prior.
  • Accumulated Depreciation & Amortization was $15.8 million for Q4 2024 at Harvard Bioscience, up from $14.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $16.6 million in Q4 2020 to a low of $14.4 million in Q4 2023.
  • A 5-year average of $15.2 million and a median of $15.1 million in 2020 define the central range for Accumulated Depreciation & Amortization.
  • Biggest YoY gain for Accumulated Depreciation & Amortization was 11.09% in 2020; the steepest drop was 15.65% in 2020.
  • Harvard Bioscience's Accumulated Depreciation & Amortization stood at $16.6 million in 2020, then decreased by 12.94% to $14.4 million in 2021, then rose by 2.75% to $14.8 million in 2022, then fell by 3.11% to $14.4 million in 2023, then rose by 9.98% to $15.8 million in 2024.
  • Per Business Quant, the three most recent readings for HBIO's Accumulated Depreciation & Amortization are $15.8 million (Q4 2024), $14.4 million (Q4 2023), and $14.8 million (Q4 2022).